Researchers published advances in CRISPR‑associated transposons (CASTs) that improve targeted DNA integration activity and retain high on‑site specificity through high‑throughput screening and mutational mapping. The work identified mutations that boost activity up to fourfold while maintaining precision—an important step toward therapeutic gene insertion without double‑strand breaks. Complementary reports on refined CRISPR variants and editing chemistries expand the editing toolbox for safer, more efficient gene therapies. Teams emphasized the remaining translational work needed to adapt systems for human cells.